NASDAQ:POAI Predictive Oncology (POAI) Stock Price, News & Analysis $1.47 -0.03 (-2.00%) Closing price 02/20/2025 04:00 PM EasternExtended Trading$1.46 -0.01 (-0.68%) As of 07:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends About Predictive Oncology Stock (NASDAQ:POAI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Predictive Oncology alerts:Sign Up Key Stats Today's Range$1.39▼$1.5550-Day Range$0.69▼$1.9552-Week Range$0.55▼$3.76Volume345,376 shsAverage Volume532,268 shsMarket Capitalization$9.80 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingHold Company OverviewPredictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.Read More… Predictive Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScorePOAI MarketRank™: Predictive Oncology scored higher than 39% of companies evaluated by MarketBeat, and ranked 738th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingPredictive Oncology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePredictive Oncology has received no research coverage in the past 90 days.Read more about Predictive Oncology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Predictive Oncology are expected to grow in the coming year, from ($2.08) to ($0.13) per share.Price to Book Value per Share RatioPredictive Oncology has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Predictive Oncology's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.55% of the float of Predictive Oncology has been sold short.Short Interest Ratio / Days to CoverPredictive Oncology has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Predictive Oncology has recently increased by 36.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPredictive Oncology does not currently pay a dividend.Dividend GrowthPredictive Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.55% of the float of Predictive Oncology has been sold short.Short Interest Ratio / Days to CoverPredictive Oncology has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Predictive Oncology has recently increased by 36.89%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.56 News SentimentPredictive Oncology has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Predictive Oncology this week, compared to 1 article on an average week.Search Interest8 people have searched for POAI on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Predictive Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.44% of the stock of Predictive Oncology is held by insiders.Percentage Held by InstitutionsOnly 9.04% of the stock of Predictive Oncology is held by institutions.Read more about Predictive Oncology's insider trading history. Receive POAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address POAI Stock News HeadlinesPredictive Oncology (NASDAQ:POAI) versus Safe Pro Group Inc. Common Stock (NASDAQ:SPAI) Head-To-Head ContrastFebruary 21 at 1:47 AM | americanbankingnews.comPredictive Oncology Closes Registered Direct OfferingFebruary 19 at 5:20 PM | globenewswire.comThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR! He says these 5 stocks are trading for less than $2 right now… But they could soon SOAR in Trump’s first 100 days.February 21, 2025 | Timothy Sykes (Ad)Predictive Oncology prices 363,336 shares at $1.50 in registered direct offeringFebruary 19 at 11:53 AM | markets.businessinsider.comPredictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 19 at 11:53 AM | finance.yahoo.comPredictive Oncology (POAI) Struggles AI-Driven Drug Repurposing BreakthroughFebruary 18 at 8:49 PM | msn.comPredictive Oncology Inc.: Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug RepurposingFebruary 18 at 3:47 PM | finanznachrichten.de2POAI : What's Going On With Predictive Oncology Shares Tuesday?February 18 at 3:47 PM | benzinga.comSee More Headlines POAI Stock Analysis - Frequently Asked Questions How have POAI shares performed this year? Predictive Oncology's stock was trading at $0.82 at the beginning of 2025. Since then, POAI stock has increased by 79.3% and is now trading at $1.47. View the best growth stocks for 2025 here. How were Predictive Oncology's earnings last quarter? Predictive Oncology Inc. (NASDAQ:POAI) posted its quarterly earnings data on Tuesday, May, 14th. The medical instruments supplier reported ($1.04) EPS for the quarter. The medical instruments supplier earned $0.42 million during the quarter. Predictive Oncology had a negative net margin of 1,012.32% and a negative trailing twelve-month return on equity of 286.30%. When did Predictive Oncology's stock split? Shares of Predictive Oncology reverse split before market open on Monday, April 24th 2023. The 1-20 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Predictive Oncology? Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Predictive Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Predictive Oncology investors own include Ford Motor (F), Wells Fargo & Company (WFC), Zomedica (ZOM), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Bank of America (BAC) and Wayfair (W). Company Calendar Last Earnings5/14/2024Today2/21/2025Next Earnings (Estimated)3/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryMedical Equipment Current SymbolNASDAQ:POAI CUSIPN/A CIK1446159 Webwww.precisiontherapeutics.com Phone(651) 389-4800FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+104.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,980,000.00 Net Margins-1,012.32% Pretax Margin-983.62% Return on Equity-286.30% Return on Assets-122.11% Debt Debt-to-Equity RatioN/A Current Ratio1.20 Quick Ratio1.06 Sales & Book Value Annual Sales$1.78 million Price / Sales5.51 Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book0.72Miscellaneous Outstanding Shares6,670,000Free Float6,438,000Market Cap$9.80 million OptionableNot Optionable Beta1.25 Social Links 10 Best Stocks to Own in 2025Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:POAI) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Predictive Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Predictive Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.